TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24880800

Group type: EXPERIMENTAL
Intervention: pegnivacogin
Number of subjects: 32

Group type: COMPARATOR
Intervention: anivamersen
Number of subjects: 32
Study: 21635359

Group type: EXPERIMENTAL
Intervention: St John's wort
Number of subjects: 12
Study: 19708803

Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg three times daily (TID)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17561929

Group type: EXPERIMENTAL
Intervention: levocetirizine 0.125 mg/kg
Number of subjects: 510

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 510
Study: 15194910

Group type: EXPERIMENTAL
Intervention: VSOP-C184 (0.015, 0.045, or 0.075 mmol Fe/kg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: VSOP-C184 (0.045 mmol Fe/kg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: VSOP-C184 (0.075 mmol Fe/kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 11897984

Group type: EXPERIMENTAL
Intervention: beclomethasone dipropionate (BDP) 168, 672, and 1344 microg/day (n = 15)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: fluticasone propionate (FP) 88, 352, and 704 microg/day (n = 15)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: fluticasone propionate (FP) dry powder inhaler (DPI) 2000 microg/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: beclomethasone dipropionate (BDP) and fluticasone propionate (FP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High exhaled nitric oxide
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High bronchodilator reversibility
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low FEV(1)/forced vital capacity ratio
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High sputum eosinophil levels
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Older age at onset of asthma
Number of subjects: 30
Study: 9854761

Group type: EXPERIMENTAL
Intervention: Medical exercise therapy
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy
Number of subjects: 208

Group type: COMPARATOR
Intervention: Self-exercise
Number of subjects: 208

Group type: COMPARATOR
Intervention: All intervention groups
Number of subjects: 208
Study: 8582540

Group type: EXPERIMENTAL
Intervention: Darglitazone 25 mg once a day for 14 days
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 2102672

Group type: EXPERIMENTAL
Intervention: Nail bed excision (Group A)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Nail bed phenolization in addition to excision (Group B)
Number of subjects: 31
Study: 355602

Group type: EXPERIMENTAL
Intervention: Baclofen (mean dose 45 mg daily)
Number of subjects: 12
Study: 31870811

Group type: COMPARATOR
Intervention: Obese patients (BMI ≥30 kg/m2) in the TCGA cohort
Number of subjects: 478

Group type: COMPARATOR
Intervention: Obese patients (BMI ≥30 kg/m2) in the COMPARZ trial
Number of subjects: 478

Group type: COMPARATOR
Intervention: Obese patients (BMI ≥30 kg/m2) in the MSK immunotherapy cohort
Number of subjects: 478

Group type: COMPARATOR
Intervention: Tumours of obese patients
Number of subjects: 478

Group type: COMPARATOR
Intervention: Peritumoral adipose tissue in obese patients
Number of subjects: 478
Study: 30741705

Group type: EXPERIMENTAL
Intervention: Cognitive orientation to daily occupational performance (CO‐OP)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Task‐specific upper extremity training (TUET)
Number of subjects: 49
Study: 27815985

Group type: EXPERIMENTAL
Intervention: Bath oil additive
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-oil containing skin cleansers
Number of subjects: 60
Study: 25344807

Group type: EXPERIMENTAL
Intervention: Rilpivirine
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Etravirine
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Emtricitabine
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Tenofovir
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Combination of tenofovir/emtricitabine/rilpivirine
Number of subjects: 169
Study: 24337447

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT) after first-line therapy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT) after second-line therapy
Number of subjects: 36
Study: 21295828

Group type: EXPERIMENTAL
Intervention: LIGHT (target liveweight of 70 kg at 161 d of age)
Number of subjects: 64

Group type: COMPARATOR
Intervention: HEAVY (target liveweight of 100 kg at 161 d of age)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: LOW (gaining liveweight at 0.5 kg/d between 161 and 175 d of age)
Number of subjects: 64

Group type: COMPARATOR
Intervention: HIGH (gaining liveweight at 1.0 kg/d between 161 and 175 d of age)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: LOW compared to HIGH LW gain
Number of subjects: 64
Study: 19514178

Group type: EXPERIMENTAL
Intervention: Auricular plaster therapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study: 17717132

Group type: EXPERIMENTAL
Intervention: hsCRP in the highest quartile
Number of subjects: 3225

Group type: EXPERIMENTAL
Intervention: hsCRP >3 mg/L in unstable angina/non-ST-elevation myocardial infarction (NSTEMI)
Number of subjects: 3225

Group type: EXPERIMENTAL
Intervention: hsCRP >10 mg/L in STEMI
Number of subjects: 3225

Group type: EXPERIMENTAL
Intervention: hsCRP concentrations
Number of subjects: 3225
Study: 15039514

Group type: EXPERIMENTAL
Intervention: Emotional writing
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control writing
Number of subjects: 37
Study: 11524194

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 40
Study: 9591496

Group type: EXPERIMENTAL
Intervention: Oral micronized 17beta‐estradiol (2 mg/d) continuously combined with dydrogesterone (2.5 mg)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Oral micronized 17beta‐estradiol (2 mg/d) continuously combined with dydrogesterone (5 mg)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Oral micronized 17beta‐estradiol (2 mg/d) continuously combined with dydrogesterone (10 mg)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Oral micronized 17beta‐estradiol (2 mg/d) continuously combined with dydrogesterone (15 mg)
Number of subjects: 135
Study: 7951368

Group type: EXPERIMENTAL
Intervention: Biken-Cam vaccine (5,000 TCID50/0.5 ml)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb vaccine with multiple puncture cylinder (7,000 TCID50/0.5 ml)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb vaccine with bifurcated needle (7,000 TCID50/0.5 ml)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 145
Study: 3310646

Group type: COMPARATOR
Intervention: minus lenses with full correction for continuous use (the reference group)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: minus lenses with full correction for distant vision only
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: bifocal lenses
Number of subjects: 240
Study: 29791259

Group type: COMPARATOR
Intervention: Usual care (information and motivational text messages)
Number of subjects: 6006

Group type: EXPERIMENTAL
Intervention: Free cessation aids (nicotine-replacement therapy or pharmacotherapy, with e-cigarettes if standard therapies failed)
Number of subjects: 6006

Group type: EXPERIMENTAL
Intervention: Free e-cigarettes (without requirement that standard therapies had been tried)
Number of subjects: 6006

Group type: EXPERIMENTAL
Intervention: Free cessation aids plus $600 in rewards for sustained abstinence
Number of subjects: 6006

Group type: EXPERIMENTAL
Intervention: Free cessation aids plus $600 in redeemable funds (money removed if cessation milestones not met)
Number of subjects: 6006

Group type: EXPERIMENTAL
Intervention: Engaged cohort (1191 employees who actively participated)
Number of subjects: 6006
Study: 26956643

Group type: EXPERIMENTAL
Intervention: Monochromatic DECT images
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Iodine map DECT images
Number of subjects: 61

Group type: COMPARATOR
Intervention: Polychromatic DECT images
Number of subjects: 61
Study: 25440215

Group type: EXPERIMENTAL
Intervention: Instrument Assisted Soft Tissue Techniques (IASTT)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 49
Study: 22406074

Group type: EXPERIMENTAL
Intervention: Protein-Creatinine Ratio (PCR)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Albumin-Creatinine Ratio (ACR)
Number of subjects: 27

Group type: COMPARATOR
Intervention: 24h Urine Protein
Number of subjects: 27
Study: 20473055

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 237

Group type: COMPARATOR
Intervention: Quetiapine
Number of subjects: 237
Study: 18928975

Group type: EXPERIMENTAL
Intervention: Hysteroscopic resection and coagulation of the base of endometrial polyps with focal atypia
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conservative treatment (control group)
Number of subjects: 21
Study: 15975991

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary balloon angioplasty (PTCA)
Number of subjects: 359

Group type: COMPARATOR
Intervention: Coronary artery bypass surgery (CABG)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Both PTCA and CABG
Number of subjects: 359
Study: 11931060

Group type: EXPERIMENTAL
Intervention: Endoscopic medial approach
Number of subjects: 30

Group type: COMPARATOR
Intervention: Open microscopic surgical technique
Number of subjects: 30
Study: 10364999

Group type: EXPERIMENTAL
Intervention: Intrathecal diamorphine 0.25 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Epidural diamorphine 5 mg
Number of subjects: 50
Study: 7863879

Group type: EXPERIMENTAL
Intervention: 200 mAs
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 140 mAs
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 80 mAs
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 20 mAs
Number of subjects: 30

Group type: COMPARATOR
Intervention: 400 mAs
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 200 mAs, 140 mAs, 80 mAs, 20 mAs
Number of subjects: 30
Study: 8254467

Group type: EXPERIMENTAL
Intervention: 100 mg of oral fluconazole once daily for 14 days
Number of subjects: 334

Group type: COMPARATOR
Intervention: 10 mg clotrimazole five times daily for 14 days
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: 100 mg of oral fluconazole once daily
Number of subjects: 334

Group type: COMPARATOR
Intervention: 10 mg clotrimazole five times daily
Number of subjects: 334
Study: 2879345

Group type: EXPERIMENTAL
Intervention: Sulbactam/Ampicillin
Number of subjects: 83

Group type: COMPARATOR
Intervention: Gentamicin/Clindamycin
Number of subjects: 83
Study: 30558330

Group type: EXPERIMENTAL
Intervention: 48 g Resistant Starch (RS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28057126

Group type: EXPERIMENTAL
Intervention: GnRH‐a (2-3 cycles)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: GnRH‐a (2 cycles)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: GnRH‐a (3 cycles)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: GnRH‐a
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control (no pretreatment)
Number of subjects: 87
Study: 24962306

Group type: EXPERIMENTAL
Intervention: Computer-related ergonomics intervention program
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 127
Study: 23228891

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Short SANS
Number of subjects: 487

Group type: COMPARATOR
Intervention: Original SANS
Number of subjects: 487

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 487
Study: 21574984

Group type: EXPERIMENTAL
Intervention: Briakinumab (200 mg at weeks 0 and 4, followed by 100 mg at week 8)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Etanercept (50 mg twice weekly at weeks 0-11)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 350
Study: 17517409

Group type: EXPERIMENTAL
Intervention: Day 4 embryo transfer
Number of subjects: 350

Group type: COMPARATOR
Intervention: Day 3 embryo transfer
Number of subjects: 350
Study: 16227328

Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine (PPV)
Number of subjects: 596

Group type: COMPARATOR
Intervention: Non-intervention group
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: PPV
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: Vaccinated group
Number of subjects: 596
Study: 12698776

Group type: EXPERIMENTAL
Intervention: Contraceptive patch (norelgestromin and ethinyl estradiol)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Contraceptive patch
Number of subjects: 146
Study: 11082083

Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac
Number of subjects: 148

Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 148
Study: 7575965

Group type: EXPERIMENTAL
Intervention: Biopaque
Number of subjects: 29

Group type: COMPARATOR
Intervention: Opaque P
Number of subjects: 29

Group type: COMPARATOR
Intervention: Vita-VMK-Paint-On 88
Number of subjects: 29
Study: 2277761

Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 7030901

Group type: EXPERIMENTAL
Intervention: Calcium infusion (35 mEq/5h)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 23
Study: 31834098

Group type: EXPERIMENTAL
Intervention: Biperiden 2 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Biperiden 4 mg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Biperiden 2 mg and 4 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Biperiden
Number of subjects: 21
Study: 31151335

Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block (PVB) with isobaric bupivacaine 0.5% (0.3 mL/kg) and dexmedetomidine (1 mcg/kg) - Group II
Number of subjects: 60

Group type: COMPARATOR
Intervention: Thoracic paravertebral block (PVB) with isobaric bupivacaine 0.5% (0.3 mL/kg) - Group I
Number of subjects: 60
Study: 29155861

Group type: EXPERIMENTAL
Intervention: Supplemented pancreatic enzymes
Number of subjects: 0
Study: 26544974

Group type: EXPERIMENTAL
Intervention: New item response model (extension of the binomial error model)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New item response model
Number of subjects: 0
Study: 23324710

Group type: EXPERIMENTAL
Intervention: Internet intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phone intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 0
Study: 22269234

Group type: EXPERIMENTAL
Intervention: Caries detector dye
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Carisolv
Number of subjects: 45

Group type: COMPARATOR
Intervention: Mechanical (conventional technique)
Number of subjects: 45
Study: 19499659

Group type: EXPERIMENTAL
Intervention: TIVA-TCI with propofol (Cpi = 4 microg/ml) and remifentanil
Number of subjects: 70

Group type: COMPARATOR
Intervention: Isoflurane anesthesia
Number of subjects: 70
Study: 17343103

Group type: EXPERIMENTAL
Intervention: New cardiovascular drugs without clinical trial outcome data
Number of subjects: 0

Group type: COMPARATOR
Intervention: Similar drugs with clinical trial outcome data
Number of subjects: 0
Study: 15194628

Group type: EXPERIMENTAL
Intervention: Pringle manoeuvre
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning before the Pringle manoeuvre
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning
Number of subjects: 68

Group type: COMPARATOR
Intervention: Without pedicle clamping
Number of subjects: 68
Study: 10666751

Group type: EXPERIMENTAL
Intervention: VVI pacing at 70 beats/min (test A)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: VVI pacing matched to intrinsic heart rate (95 +/- 11 beats/min) (test B)
Number of subjects: 15
Study: 9059545

Group type: EXPERIMENTAL
Intervention: 50 mg of oral losartan
Number of subjects: 9
Study: 8198030

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin, 0.6 mg/hour
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 3556123

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 250 mg b.d.
Number of subjects: 140

Group type: COMPARATOR
Intervention: Augmentin 375 mg t.d.s.
Number of subjects: 140

Group type: COMPARATOR
Intervention: Cefaclor 250 mg t.d.s.
Number of subjects: 140
Study: 30741081

Group type: EXPERIMENTAL
Intervention: Elastic band exercise (45-60 min per session, 3 days a week for 8 weeks)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 70
Study: 30327403

Group type: EXPERIMENTAL
Intervention: Exercise referral schemes enhanced by self-management strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-utility analysis using EQ-5D-5L
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Capability well-being measured using ICECAP-O
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Healthcare costs (hospitalisations, emergency visits, appointments)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social care costs (community care)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-consequence analysis
Number of subjects: 0
Study: 28961905

Group type: EXPERIMENTAL
Intervention: Surotomycin 250 mg twice daily
Number of subjects: 577

Group type: COMPARATOR
Intervention: Vancomycin 125 mg four times daily
Number of subjects: 577
Study: 26182747

Group type: EXPERIMENTAL
Intervention: Endovascular treatment for peripheral vascular disease
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Endovascular treatment for tibioperoneal lesions
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Endovascular treatment for carotid lesions
Number of subjects: 25
Study: 23749840

Group type: EXPERIMENTAL
Intervention: Arikace 560 mg
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 20472124

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5%
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 18977243

Group type: EXPERIMENTAL
Intervention: Tailored Internet-plus-email intervention (access to a tailored website and weekly emails)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 156
Study: 16331118

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 801

Group type: COMPARATOR
Intervention: Ramipril 5 mg
Number of subjects: 801

Group type: COMPARATOR
Intervention: Ramipril 10 mg
Number of subjects: 801
Study: 12652454

Group type: EXPERIMENTAL
Intervention: C. pneumoniae infection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro studies and animal models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human intervention studies
Number of subjects: 0
Study: 10830757

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 60
Study: 8971618

Group type: EXPERIMENTAL
Intervention: Prophylactic azithromycin
Number of subjects: 654

Group type: COMPARATOR
Intervention: Control group (no prophylactic azithromycin)
Number of subjects: 654
Study: 1281442

Group type: EXPERIMENTAL
Intervention: Commercial allergen extracts
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Fresh, standardized foods
Number of subjects: 17
Study: 2579462

Group type: EXPERIMENTAL
Intervention: Continuous subcuticular absorbable (Dexon) suture
Number of subjects: 205
Study: 31570509

Group type: EXPERIMENTAL
Intervention: Mass method of dosing epinephrine (milligrams per kilogram)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Volume method of dosing epinephrine (milliliters per kilogram)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Mass method doses
Number of subjects: 70

Group type: COMPARATOR
Intervention: Volume method doses
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 70
Study: 29616285

Group type: EXPERIMENTAL
Intervention: Coated TKA
Number of subjects: 122

Group type: COMPARATOR
Intervention: Standard TKA
Number of subjects: 122
Study: 27441950

Group type: EXPERIMENTAL
Intervention: Localized muscle fatigue (LMF) induced using a custom fatigue protocol with plantar-flexion and dorsiflexion exertions at 12 cycles per minute at isotonic loads of 70% and 30% of individual maximal voluntary isometric strength.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Localized muscle fatigue (LMF) induced using a custom fatigue protocol.
Number of subjects: 22
Study: 25416537

Group type: EXPERIMENTAL
Intervention: Cognitive intervention through a training program for picture book reading
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (lectures about elderly health maintenance)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Cognitive intervention for participants with mild cognitive impairment (MCI)
Number of subjects: 58
Study: 23155344

Group type: EXPERIMENTAL
Intervention: PUFA group (omega-3 fish oil lipid emulsion)
Number of subjects: 66

Group type: COMPARATOR
Intervention: PN group
Number of subjects: 66
Study: 19156679

Group type: EXPERIMENTAL
Intervention: Warned malingerers
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Unwarned malingerers
Number of subjects: 67

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 67
Study: 17179910

Group type: EXPERIMENTAL
Intervention: 1000 mg hydrotalcite
Number of subjects: 53

Group type: COMPARATOR
Intervention: 10 mg famotidine
Number of subjects: 53
Study: 15726880

Group type: EXPERIMENTAL
Intervention: Itraconazole (Traconal 100 mg)
Number of subjects: 24
Study: 11868919

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9797644

Group type: EXPERIMENTAL
Intervention: Running training for 13 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (maintained usual lifestyle)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Runners after 9 days of detraining
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Postprandial lipaemia and post‐heparin LPL activity
Number of subjects: 14